A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

Inclusion Criteria: * Diagnosis of schizophrenia according to DSM-IV-TR criteria * Has been able to achieve outpatient status for more than 3 months in the past year * Body mass index (BMI) of 18.5 to 40.0 kg/m2 (inclusive) * Resides in a stable living situation * Willing and able to be confined to an inpatient study unit for 2 weeks or longer Exclusion Criteria: * History of poor or inadequate clinical response to treatment with aripiprazole * History of treatment resistance * Known or suspected intolerance of, allergy, or hypersensitivity to aripiprazole, its ingredients, other antipsychotic agent, or INTRALIPID (including peanuts, soy, egg, or glycerol) * Diagnosis of current substance dependence (including alcohol) * Pregnant, lactating, or breastfeeding * Receipt of any antipsychotic medication by IM injection within 60 days before Screening * Current involuntary hospitalization or incarceration * Hospitalized for more than 30 days during the 90 days before Screening Additional inclusion/exclusion criteria may apply.